Persian

Beraksurf

Beractant

Category: Children and Infants

Beraksurf® is a pulmonary surfactant containing bovine lung extract which used for the treatment or prophylaxis of Respiratory Distress Syndrome (RDS) in premature infants. Beraksurf manufactured as sterile, pyrogen-free intratracheal suspension and it should be administered intratracheally only.

General Information

What is the use of Beraksurf?

Beraksurf ® is used to treat and prevent neonatal respiratory distress syndrome (RDS). Respiratory distress syndrome usually occurs in premature infants. These babies have a deficiency in a substance called surfactant in their lungs that prevents the lungs from sticking together, and the baby is unable to breathe normally. Surfactant therapy may also be helpful in cases of secondary inactivation of the surfactant, such as ventilated infants with severe pneumonia, pulmonary hemorrhage, or meconium aspiration syndrome.

More About Beraksurf

How to store and use Beraksurf?

Beraksurf ® should be stored in the refrigerator (at 2 to 8 ° C). It should be warmed (not shaken) at room temperature for at least 20 minutes or at least 8 minutes before injection.

What important information should I know about Beraksurf ®?

Beraksurf ® should only be prescribed in hospitals equipped with ventilation and the possibility of monitoring infants with RDS and by specialists trained in neonatal care and resuscitation.

Dosage form of Beraksurf ®

Sterile, pyrogen-free intratracheal suspension, in two following dosage:

• 4 ml vial, 25 mg/ml, 100 mg phospholipid

• 8 ml vial, 25 mg/ml, 200 mg phospholipid

Precautions:

Beraksurf® is just for intratracheal administration. Avoid vigorous shaking of the product.

Beraksurf® can change oxygenation and pulmonary compliance very quickly, therefore its administration should be under direct supervision of specialists well experienced with intubation, ventilator management, and general care of preterm infants. Treated Infants should be frequently monitored with measurement of systemic oxygen and carbon dioxide.

If during administration, temporary bradycardia and also decrease in oxygen level occurred stop dosing procedure and stabilize the condition and then resume the dosing procedure.

Mechanism of Action of Beraksurf®:

Beraksurf® (Beractant) is a substitute for natural pulmonary surfactant in surfactant replacement therapy. In infants suffering from Respiratory Distress Syndrome (RDS) or in preterm infants with risk of developing RDS, this surfactant is not produced or is not present in enough amount, therefore they can’t breathe normally. Beractant reduces surface tension between air and alveolar surface and prevent collapsing alveolus during respiration and thus helps infant breath normally.

For adverse event report and contact with patient support unit

Click Here

First slide

Published Articles